



RNS Number : 4371D
EKF Diagnostics Holdings PLC
03 March 2022

EKF Diagnostics Holdings plc
("EKF", the "Company" or the "Group")

Notice of Preliminary Results

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-listed point-of-care business, will announce its preliminary results for the year ended 31 December 2021 on Tuesday 29 March 2022.

Investor Presentation

Mike Salter, Chief Executive Officer, and Marc Davies, Chief Financial Officer, will be hosting a live online presentation relating to the final results via the Investor Meet Company platform at 4.30 pm on Tuesday 29 March 2022. The presentation is open to all existing and potential shareholders.

Investors can sign up to Investor Meet Company for free and register for the presentation [here:](https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor)
<https://www.investormeetcompany.com/ekf-diagnostics-holdings-plc/register-investor>

Investors who already follow EKF on the Investor Meet Company platform will automatically be invited.

Questions can be submitted pre-event via your IMC dashboard or in real time during the presentation, via the "Ask a Question" function. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory notifications. A recording of the presentation, a PDF of the slides used, and responses to the Q&A session will be available on the Investor Meet Company platform afterwards.

EKF Diagnostics Holdings plc
Christopher Mills, Non-Executive Chairman
Mike Salter, CEO
Marc Davies, CFO

www.ekfdiagnostics.com
Tel: +44 (0)29 2071 0570

Singer Capital Markets (Nominated Adviser & Joint Broker)

Tel: +44 (0)20 7496 3000

Aubrey Powell / George Tzimas / Tom Salvesen

Investec Bank plc (Joint Broker)
Gary Clarence / Daniel Adams / Ben Farrow

Tel: +44 (0)20 7597 4000

Walbrook PR Limited
Paul McManus / Lianne Applegarth

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com
Mob: +44 (0)7980 541 893 / +44 (0)7584 391 303

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

EKF is a leading point-of-care diagnostics and central laboratory assay manufacturer with an estimated 80,000 hemoglobin, hematocrit, HbA1c, glucose and lactate analysers in regular use across more than 100 countries. EKF specialises in developing tests for use in anemia and diabetes diagnosis and management, as well as providing a portfolio of reagents for use in clinical chemistry analysers.

EKF specialises in the development, production and worldwide distribution of point-of-care analyzers and clinical chemistry reagents for use in hospital and research laboratories, doctor's offices, blood banks and for in-field anaemia screening programmes. EKF is also a bulk manufacturer of enzymes and has custom manufacturing facilities across sites in the US, UK and Europe for a variety of life science products. Driven by customer demand EKF has invested significantly in increasing the Company's fermentation capacity. The Company's capabilities and capacity in contract manufacturing for sample collection, tests and test kits have seen dramatic growth following strong demand for during the COVID-19 pandemic, and these income streams are now being diversified for application to other non-COVID areas of diagnostic testing, molecular disease and forensic test manufacture.

In May 2021, EKF outlined its strategy through to 2024 for delivering additional growth. As well as the growth expected in Contract Manufacturing across Life Sciences, molecular diagnostics and other applications, the Company expects to leverage existing distribution channels for organic growth, both in the core business and from additional products to expand the core range, but also through executing earnings enhancing acquisitions and delivering further value creating investments associated with the preferred partnership agreement with Mount Sinai Innovation Partners.

In October 2021, EKF completed the acquisition of Advanced Diagnostic Laboratory LLC, a Texas based testing laboratory certified under the Clinical Laboratory Improvement Amendments ("CLIA") for high complexity testing. The laboratory provides testing for a variety of clinical, forensic and microbiological sample types using a range of analytical techniques. This acquisition positions EKF as a leading 'one stop' provider of diagnostic products and services from sample collection to results.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NORDZGGFVZFGZZM admin Notice of Results 32503141 A Thu, 03/03/2022 - 07:00 LSE RNS
Advance Notice of Results EKF